Mounjaro Injection, Solution
Product Images NDC 50090-8024

Product Visual Gallery

This gallery contains 64 technical images submitted to the FDA as part of the official labeling for Mounjaro (NDC 50090-8024). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500908024)

MOUNJARO (tirzepatide) injection, 5 mg/0.5 mL, in a prefilled syringe. The label indicates 4 syringes per box and includes storage instructions, manufacturer A-S Medication Solutions, and product NDC 50090-8024.*

FDA Label Image

Figure (Logo)

FDA Label Image

Figure (Moun Pen Ifu 1 V3)

MOUNJARO 5 mg/0.5 mL injection, solution in a prefilled subcutaneous injection pen. The device is primarily white with a gray, purple, and green dose adjustment feature. Labeler is A-S Medication Solutions.*

FDA Label Image

Figure (Moun Pen Ifu 10 V2)

An instructional diagram showing a clear injection needle cap with a gray plunger inside, labeled to identify the "Gray Plunger" component. This image likely serves to illustrate part of the MOUNJARO injection device.*

FDA Label Image

Figure (Moun Pen Ifu 2 V2)

Diagram of the MOUNJARO injection pen showing labeled parts including a purple injection button at the top, lock ring, indicator, lock/unlock symbols, medicine reservoir, clear base, and gray base cap with bottom and needle end noted.*

FDA Label Image

Figure (Moun Pen Ifu 3 V2)

An illustration of a MOUNJARO (tirzepatide) 5 mg/0.5 mL subcutaneous injection pen highlighting the location of the expiration date on the device. The expiration date is indicated in a black window near the top of the pen, circled and pointed to by a label.*

FDA Label Image

Figure (Moun Pen Ifu 4a V1)

An illustration showing recommended subcutaneous injection sites for MOUNJARO (tirzepatide) 5 mg/0.5 mL injection solution. Highlighted areas in purple include the abdomen around the navel and the front of both thighs.*

FDA Label Image

Figure (Moun Pen Ifu 4b V1)

An illustration showing suggested injection sites on the upper outer arms, highlighted in purple, for subcutaneous administration of MOUNJARO (tirzepatide) injection solution.*

FDA Label Image

Figure (Moun Pen Ifu 5 V2)

An instructional diagram showing how to remove a gray base cap from the clear base of a MOUNJARO (tirzepatide) injection pen prior to subcutaneous administration. The image highlights a hand holding the pen and indicates the unlocking mechanism near the top of the device.*

FDA Label Image

Figure (Moun Pen Ifu 6 V2)

An instructional illustration showing a hand holding a pen-like injection device administering a subcutaneous injection into the abdomen of a person, demonstrating correct injection technique for a medication in injection form.*

FDA Label Image

Figure (Moun Pen Ifu 7 V2)

An instructional diagram showing how to unlock a MOUNJARO injection pen by rotating the base with a red arrow indicating the direction. The image depicts a hand holding the injection pen to demonstrate the unlocking step.*

FDA Label Image

Figure (Moun Pen Ifu 8 V2)

An instructional illustration showing a person's hand holding an injection pen near the abdomen, demonstrating the subcutaneous injection technique for administering medication.*

FDA Label Image

Figure (Moun Pen Ifu 9 V2)

An instructional illustration showing the gray plunger component at the tip of a subcutaneous injection device, likely for the MOUNJARO injection solution. The image highlights the part labeled as 'Gray Plunger' within the injection mechanism.*

FDA Label Image

Figure (Moun Qr)

FDA Label Image

Structural Formula (Moun Uspi Chem Struc)

Chemical structure of tirzepatide, the active ingredient in MOUNJARO injection solution. The image displays a complex molecular formula including a peptide sequence with amino acid abbreviations and a fatty acid moiety.*

FDA Label Image

Figure 1 (Moun Uspi F1 V1)

A line graph depicting insulin levels (mIU/L) over time (minutes) across two phases. The graph compares four datasets: Placebo-Baseline, Placebo-Week 28, Tirzepatide 15 mg-Baseline, and Tirzepatide 15 mg-Week 28, showing changes in insulin concentration for each group, with time points up to 120 minutes.*

FDA Label Image

Figure 2 (Moun Uspi F2 V1)

Line graph showing changes in HbA1c (%) over weeks post randomization for MOUNJARO injection solution in 5 mg, 10 mg, and 15 mg doses, compared to Semaglutide 1 mg. The x-axis represents time in weeks up to 40 weeks; the y-axis shows HbA1c percentages from 5.5% to 8.5%. Data points show a decrease in HbA1c over time for all doses, with MOUNJARO doses generally achieving lower HbA1c levels than Semaglutide at the 40-week mark.*

FDA Label Image

Figure (Moun Vial Ifu 1 V1)

An illustration of a Mounjaro 5 mg/0.5 mL injection vial showing the protective cap on top and the rubber stopper located under the cap, labeling key vial components.*

FDA Label Image

Figure (Moun Vial Ifu 10 V1)

An instructional illustration showing a hand holding a vial and another hand inserting a syringe needle into the vial. An arrow indicates the direction of needle insertion for drawing medication from the vial.*

FDA Label Image

Figure (Moun Vial Ifu 11 V1)

An instructional illustration showing a person drawing medication from a vial into a syringe. The hands hold the vial and syringe, with an arrow indicating the direction of syringe plunger movement to withdraw the liquid medication.*

FDA Label Image

Figure (Moun Vial Ifu 12 V1)

An instructional illustration showing a hand holding a syringe injecting subcutaneously into the skin of an arm. Next to it is a close-up image of a syringe barrel with black measurement markings from 0.0 to 0.5 mL to indicate dosage volume.*

FDA Label Image

Figure (Moun Vial Ifu 13 V1)

An instructional black-and-white line drawing showing two hands preparing an injection solution with a syringe and vial, demonstrating medication withdrawal technique.*

FDA Label Image

Figure (Moun Vial Ifu 14 V1)

An instructional illustration showing a hand holding a vial upside down while drawing liquid into a syringe. An inset zooms in on the syringe barrel, highlighting measurement markings from 0.1 to 0.5 mL.*

FDA Label Image

Figure (Moun Vial Ifu 15 V1)

An instructional illustration showing a hand holding a vial in one hand and a syringe in the other, with an upward arrow indicating the action of drawing medication from the vial into the syringe.*

FDA Label Image

Figure (Moun Vial Ifu 16 V1)

An instructional diagram showing recommended injection sites for a subcutaneous injection. The sites highlighted are on the abdomen around the navel and on the outer thigh areas, indicating where to administer the injection.*

FDA Label Image

Figure (Moun Vial Ifu 17 V1)

An anatomical illustration showing the human body from the back, highlighting the upper arm injection sites. The graphic indicates the recommended subcutaneous injection areas for the medication.*

FDA Label Image

Figure (Moun Vial Ifu 18 V1)

An instructional line drawing showing a person holding a syringe to their abdominal area, indicating the subcutaneous injection site for administering medication, with an arrow pointing to the injection area.*

FDA Label Image

Figure (Moun Vial Ifu 19 V1)

An instructional illustration showing a person administering a subcutaneous injection into their abdominal area. The hand holds a syringe or injection pen positioned near the skin above the waistband, demonstrating the injection procedure for a medication such as MOUNJARO (tirzepatide).*

FDA Label Image

Figure (Moun Vial Ifu 2 V1)

Illustration of a prefilled syringe for MOUNJARO 5 mg/0.5 mL injection showing labeled parts including the needle shield, needle, syringe body with volume markings, plunger tip, and plunger. An inset highlights the 0.5 mL measurement on the syringe barrel.*

FDA Label Image

Figure (Moun Vial Ifu 20 V1)

An instructional illustration showing a hand holding a syringe with a needle aimed at the neck area of a person's skin, indicating the injection site or technique for subcutaneous administration.*

FDA Label Image

Figure (Moun Vial Ifu 3 V1)

An instructional illustration showing a hand grasping a small vial, with the other hand removing or lifting the cap upwards. The image likely demonstrates vial cap removal or preparation for injection.*

FDA Label Image

Figure (Moun Vial Ifu 4 V1)

Black and white line drawing depicting a pair of hands holding an injection vial. One hand is gripping the vial, while the other is peeling or removing a protective cap or seal from the vial top. This image likely serves as an instructional illustration related to medication preparation before injection.*

FDA Label Image

Figure (Moun Vial Ifu 5 V1)

An instructional illustration showing a person using a syringe to inject a solution into a section of skin on the arm or leg. The image depicts subcutaneous injection technique with hands holding and pinching the skin to administer the dose.*

FDA Label Image

Figure (Moun Vial Ifu 6 V1)

An instructional illustration showing two hands peeling off a protective backing from a small adhesive patch or device, likely related to preparing a subcutaneous injection for use.*

FDA Label Image

Figure (Moun Vial Ifu 7 V1)

An illustration showing a step in medication preparation where a strip or band is being peeled or unwrapped from a cylindrical container or device, likely related to the MOUNJARO injection solution. The image depicts a hand interacting with the device.*

FDA Label Image

Figure (Moun Vial Ifu 8 V1)

Illustration showing hands holding a pen-like injection device being prepared by removing a cap or cover, indicated by a left-pointing arrow. This instructional image likely demonstrates part of the process to prepare a subcutaneous injection pen, consistent with the MOUNJARO injection solution product.*

FDA Label Image

Figure (Moun Vial Ifu 9 V1)

An instructional illustration showing proper handling of a syringe. The image depicts a hand holding the syringe and another hand pushing down the plunger to expel air. An inset shows a close-up of the syringe barrel with volume markings from 0.1 to 0.5 mL and air bubbles at the plunger end.*

FDA Label Image

Figure (Moun Vial Md Ifu 14 V1)

An instructional illustration showing hands drawing a liquid from a vial into a syringe, with an enlarged inset of the syringe barrel indicating measurement markings from 0.1 to 0.6 mL. The image emphasizes correct technique for preparing an injection dose.*

FDA Label Image

Figure (Moun Vial Md Ifu 2 V1)

An instructional diagram of a syringe for injection solution, labeled with parts including the needle shield, needle, syringe body with volume markings from 0.1 to 1.0 mL, plunger tip, and plunger. The diagram highlights the 0.5 mL measurement on the syringe body, relevant for subcutaneous injection dosing.*

FDA Label Image

Figure (Moun Vial Md Ifu 9 V1)

An instructional diagram showing a hand holding a syringe, with an arrow indicating downward movement, suggesting how to prepare the injection. A close-up inset of the syringe's calibrated barrel indicates measurement markings from 0.1 to 0.6 mL.*

FDA Label Image

Figure (Mounjaro Kp 1 Pen V1)

MOUNJARO 5 mg/0.5 mL injection pen for subcutaneous use, containing tirzepatide. The injection pen is predominantly white with a clear dose window displaying the number 0, and features a purple cap at the end. It is supplied by A-S Medication Solutions.*

FDA Label Image

Figure (Mounjaro Kp 10 Dial Clicks V1)

An instructional illustration showing a hand peeling back a protective film or label from a device, indicated by a downward red arrow. The image depicts the initial step in preparing a MOUNJARO injection pen for use.*

FDA Label Image

Figure (Mounjaro Kp 11 Dial Zoom V1)

MOUNJARO 5 mg per 0.5 mL injection solution for subcutaneous use in a single-dose prefilled pen. The label includes the proprietary name MOUNJARO, the active ingredient tirzepatide, and the strength. The labeler is A-S Medication Solutions, with NDC 50090-8024. The label features dosage instructions and storage information.*

FDA Label Image

Figure (Mounjaro Kp 12 Tap V1)

An illustration showing a hand holding a syringe for subcutaneous injection, with another hand's finger tapping the syringe and a red arrow pointing to the needle area, possibly indicating a step in preparing or using the injection.*

FDA Label Image

Figure (Mounjaro Kp 13 5sec Hold V1)

An instructional illustration showing a hand holding a prefilled injection pen with an upwards arrow, indicating removal of the cap. An inset zooms in on the needle tip with a droplet, accompanied by a stopwatch icon, suggesting a timing step after needle exposure.*

FDA Label Image

Figure (Mounjaro Kp 14 Zero Dial Zoom V1)

MOUNJARO 5 mg/0.5 mL injection solution for subcutaneous use in a prefilled pen device. The label displays the proprietary name MOUNJARO and specifies the active ingredient tirzepatide. The labeler is A-S Medication Solutions. The pen is designed for human prescription drug use.*

FDA Label Image

Figure (Mounjaro Kp 15 Inj Sites V1)

An anatomical illustration showing recommended subcutaneous injection sites for MOUNJARO (tirzepatide) injection 5 mg/0.5 mL. Injection areas highlighted include the abdomen, front thigh, and upper arm, depicted on front and back views of a human figure.*

FDA Label Image

Figure (Mounjaro Kp 16 Dial 1 Dose V1)

An instructional diagram showing a hand dialing the dose on a MOUNJARO (tirzepatide) injection pen. The image illustrates the step of turning the dial to set the desired dose prior to subcutaneous injection.*

FDA Label Image

Figure (Mounjaro Kp 17 Dial 1 Zoom V1)

MOUNJARO 5 mg/0.5 mL injection, solution for subcutaneous use. The image shows the drug name MOUNJARO prominently, along with the generic name tirzepatide. The label includes dosage strength and route of administration. The labeler is A-S Medication Solutions, and the product NDC is 50090-8024.*

FDA Label Image

Figure (Mounjaro Kp 18 Insert Needle V1)

Instructional illustration showing the injection of MOUNJARO (tirzepatide) solution, 5 mg/0.5 mL, subcutaneously into the abdominal area. The image depicts a hand holding the injection pen and an arrow indicating the direction of injection into the skin.*

FDA Label Image

Figure (Mounjaro Kp 19 Push Hold V1)

An instructional diagram showing a hand holding a prefilled syringe injecting a subcutaneous solution. The image includes an arrow labeled 'PUSH' indicating the injection action and a clock icon indicating to hold the injection for 5 seconds.*

FDA Label Image

Figure (Mounjaro Kp 2 Pen Parts V2)

An instructional diagram showing the components of a MOUNJARO (tirzepatide) injection pen and pen needle parts. The pen components labeled include pen cap with clip, cartridge with plunger, cartridge holder, pen body with label, dose window with dose indicator, and dose knob. Additionally, parts of the pen needle—outer needle shield, inner needle shield, needle, and paper tab—are illustrated, noting that needles are not included.*

FDA Label Image

Figure (Mounjaro Kp 20 Remove V1)

An instructional illustration showing the injection of a solution into the abdomen using an injection pen device held in one hand. The image emphasizes the direction of injection with a left-pointing arrow, indicating the proper technique for subcutaneous administration.*

FDA Label Image

Figure (Mounjaro Kp 21 Cotton Ball V1)

An instructional illustration showing a hand inserting a subcutaneous injection needle into the abdominal area, indicated by a red arrow pointing toward the injection site.*

FDA Label Image

Figure (Mounjaro Kp 22 Recap Shield V1)

An illustration depicting the removal of a protective cap from the needle of an injection pen. The image shows a hand holding the pen, with an arrow indicating the cap being pulled off, suggesting preparation for subcutaneous injection.*

FDA Label Image

Figure (Mounjaro Kp 23 Remove Needle V1)

An instructional diagram showing a hand removing or placing a cap on a pen injector device. The device has a red band or label near the cap area, indicating part of the injection preparation process.*

FDA Label Image

Figure (Mounjaro Kp 24 Recap Pen V1)

An instructional illustration showing a pen injection device with its cap being removed by pulling it in the direction indicated by a red arrow. The image demonstrates the first step in preparing an injection, likely relevant to the MOUNJARO subcutaneous injection solution.*

FDA Label Image

Figure (Mounjaro Kp 3 Wash V1)

An illustration showing two hands washing with soap bubbles, indicating handwashing instructions or hygiene practices often included in medication usage guidelines.*

FDA Label Image

Figure (Mounjaro Kp 4 Uncap V1)

An instructional illustration showing a syringe with the needle cap attached; a red arrow points leftward, indicating the direction to pull off the needle cap before injection.*

FDA Label Image

Figure (Mounjaro Kp 5 Wipe V1)

Instructional illustration showing a person removing a cap from a vial or container using a cloth or tissue, with a red arrow indicating the direction to twist or pull the cap off.*

FDA Label Image

Figure (Mounjaro Kp 6 New Needle Tab V1)

An instructional diagram showing a hand removing or twisting the cap from a pen-style injector device, indicated by a red curved arrow. This likely relates to preparing the MOUNJARO (tirzepatide) injection for use.*

FDA Label Image

Figure (Mounjaro Kp 7 Attach Needle V1)

An instructional illustration showing how to rotate the dial or knob of a pen-style injector, indicated by red arrows guiding a twisting motion on the device's end.*

FDA Label Image

Figure (Mounjaro Kp 8 Outer Shield V1)

An instructional diagram showing how to remove the cap from an injection pen. The illustration features a close-up view of the pen tip with the cap being pulled straight up, indicated by a red arrow pointing upward.*

FDA Label Image

Figure (Mounjaro Kp 9 Inner Shield V1)

An instructional diagram showing the removal of a needle cap from an injection pen or device. The image depicts a needle cap above the injection pen with an upward-pointing arrow indicating the direction to pull the cap off before use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.